Sugi Predict

Sugi Predict / Targets / MAP3K2

MAP3K2

Mitogen-activated protein kinase kinase kinase 2 · Q9Y2U5 · MAP3K2 on Sugi Atlas →

3,856 patent compounds predicted against MAP3K2, 3,086 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL371886 SCHEMBL371886 0.60 3/20
SCHEMBL372007 SCHEMBL372007 0.56 3/20
SCHEMBL372225 SCHEMBL372225 0.56 3/20
SCHEMBL371939 SCHEMBL371939 0.55 3/20
SCHEMBL372271 SCHEMBL372271 0.55 3/20
SCHEMBL371758 SCHEMBL371758 0.87 2/20
SCHEMBL371897 SCHEMBL371897 0.82 2/20
SCHEMBL372005 SCHEMBL372005 0.73 2/20
SCHEMBL372006 SCHEMBL372006 0.73 2/20
SCHEMBL371938 SCHEMBL371938 0.73 2/20
SCHEMBL372270 SCHEMBL372270 0.73 2/20
SCHEMBL371898 SCHEMBL371898 0.57 2/20
SCHEMBL168388 SCHEMBL168388 0.55 2/20
Motesanib Motesanib (SCHEMBL187470) 1.00 1/20
Amg-900 Amg-900 (SCHEMBL503564) 1.00 1/20
Motesanib Motesanib (SCHEMBL445079) 0.98 1/20
Motesanib Motesanib (SCHEMBL446673) 0.95 1/20
SCHEMBL581178 SCHEMBL581178 0.84 1/20
SCHEMBL580354 SCHEMBL580354 0.84 1/20
SCHEMBL581542 SCHEMBL581542 0.82 1/20

Clinical trials — most relevant to MAP3K2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies PHASE1/PHASE2RECRUITING
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Histiocytic Disorder Follow-up Study nanRECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy nanUNKNOWN
Biomarker Analysis of Gastrointestinal Cancer nanUNKNOWN
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAP3K2 binder may also engage these)

ProteinNameSimilarity
Q61083 — 1.000 Q61083 →
Q61084 — 1.000 Q61084 →
MAP3K3 Mitogen-activated protein kinase kinase kinase 3 1.000 landscape →
O35346 — 0.989 O35346 →
PTK2 Focal adhesion kinase 1 0.988 landscape →
P34152 — 0.987 P34152 →
Q62073 — 0.987 Q62073 →
A2VDU3 — 0.987 A2VDU3 →
Q5R5M7 — 0.986 Q5R5M7 →
P0C8E4 — 0.986 P0C8E4 →
P34908 — 0.985 P34908 →
A7E3S4 — 0.985 A7E3S4 →
Q69Z98 — 0.985 Q69Z98 →
Q00944 — 0.985 Q00944 →
Q5U2Z7 — 0.984 Q5U2Z7 →
Q5RFL3 — 0.984 Q5RFL3 →
Q28GW8 — 0.984 Q28GW8 →
P09560 — 0.984 P09560 →
Q91738 — 0.984 Q91738 →
P11345 — 0.984 P11345 →
Q812E4 — 0.984 Q812E4 →
BRSK2 Serine/threonine-protein kinase BRSK2 0.984 landscape →
Q8TDW5 — 0.983 Q8TDW5 →
RAF1 RAF proto-oncogene serine/threonine-protein kinase 0.983 landscape →
Q03141 — 0.983 Q03141 →
Q8C0D4 — 0.983 Q8C0D4 →
Q8BYW1 — 0.983 Q8BYW1 →
Q91821 — 0.983 Q91821 →
MAP3K7 Mitogen-activated protein kinase kinase kinase 7 0.983 landscape →
Q5RJI5 — 0.983 Q5RJI5 →